199 related articles for article (PubMed ID: 31789626)
1. Tumor lysis syndrome associated with bortezomib: A post-hoc analysis after signal detection using the US Food and Drug Administration Adverse Event Reporting System.
Sanagawa A; Hotta Y; Kondo M; Nishikawa R; Tohkin M; Kimura K
Anticancer Drugs; 2020 Feb; 31(2):183-189. PubMed ID: 31789626
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study.
Kondo M; Hotta Y; Yamauchi K; Sanagawa A; Komatsu H; Iida S; Kimura K
BMC Cancer; 2020 Nov; 20(1):1117. PubMed ID: 33203424
[TBL] [Abstract][Full Text] [Related]
3. Management of tumor lysis syndrome in patients with multiple myeloma during bortezomib treatment.
Wang L; Jian Y; Yang G; Gao W; Wu Y; Zuo L
Clin J Oncol Nurs; 2015 Feb; 19(1):E4-7. PubMed ID: 25689664
[TBL] [Abstract][Full Text] [Related]
4. Tumor Lysis Syndrome Associated with Monoclonal Antibodies in Patients with Multiple Myeloma: A Pharmacovigilance Study Based on the FAERS Database.
Xia S; Gong H; Zhao Y; Guo L; Wang Y; Ma R; Zhang B; Sarangdhar M; Noguchi Y; Yan M
Clin Pharmacol Ther; 2023 Jul; 114(1):211-219. PubMed ID: 37086211
[TBL] [Abstract][Full Text] [Related]
5. High Risk of Tumor Lysis Syndrome in Symptomatic Patients with Multiple Myeloma with Renal Dysfunction Treated with Bortezomib.
Oiwa K; Morita M; Kishi S; Okura M; Tasaki T; Matsuda Y; Tai K; Hosono N; Ueda T; Yamauchi T
Anticancer Res; 2016 Dec; 36(12):6655-6662. PubMed ID: 27919998
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Analysis of Bortezomib-Induced Adverse Events Using the Japanese Real-World Database.
Satoki A; Uchida M; Fujiwara M; Uesawa Y; Shimizu T
Oncology; 2022; 100(3):188-194. PubMed ID: 34915520
[TBL] [Abstract][Full Text] [Related]
7. Cardiac Adverse Events Associated with Multiple Myeloma Patients Treated with Proteasome Inhibitors.
Fujiwara M; Uchida M; Endo M; Goto M; Shimizu T
Oncology; 2023; 101(5):343-348. PubMed ID: 36889294
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
9. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
10. Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.
Terpos E; Politou M; Rahemtulla A
J Cancer Res Clin Oncol; 2004 Oct; 130(10):623-5. PubMed ID: 15449188
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib-associated tumor lysis syndrome.
Shely RN; Ratliff PD
Pharmacotherapy; 2014 May; 34(5):e34-7. PubMed ID: 24390940
[TBL] [Abstract][Full Text] [Related]
12. Tumor lysis syndrome in patients with light chain multiple myeloma: report of two cases.
Chang H; Lee SY; Tang TC
Chang Gung Med J; 2011; 34(6 Suppl):70-5. PubMed ID: 22490464
[TBL] [Abstract][Full Text] [Related]
13. Acute kidney injury in bortezomib-treated patients with multiple myeloma.
Song SM; Jeon J; Jang HR; Kim K; Huh W; Kim YG; Lee JE
Nephrol Dial Transplant; 2023 Aug; 38(9):2077-2085. PubMed ID: 36662030
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of the Association of Hand-Foot Syndrome with Anticancer Drugs Using the US Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) Databases].
Sasaoka S; Matsui T; Abe J; Umetsu R; Kato Y; Ueda N; Hane Y; Motooka Y; Hatahira H; Kinosada Y; Nakamura M
Yakugaku Zasshi; 2016; 136(3):507-15. PubMed ID: 26935094
[TBL] [Abstract][Full Text] [Related]
15. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.
Jaskiewicz AD; Herrington JD; Wong L
Pharmacotherapy; 2005 Dec; 25(12):1820-5. PubMed ID: 16305302
[TBL] [Abstract][Full Text] [Related]
16. Ixazomib-associated tumor lysis syndrome in multiple myeloma: A case report.
Jin F; Yang M; Chen Y; Jiang L; Liu L
Medicine (Baltimore); 2020 Nov; 99(45):e22632. PubMed ID: 33157919
[TBL] [Abstract][Full Text] [Related]
17. Adverse event reporting patterns of concomitant botanical dietary supplements with CYP3A4 interactive & CYP3A4 non-interactive anticancer drugs in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Fahim SM; Mishuk AU; Cheng N; Hansen R; Calderón AI; Qian J
Expert Opin Drug Saf; 2019 Feb; 18(2):145-152. PubMed ID: 30576263
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
Wittayanukorn S; Qian J; Johnson BS; Hansen RA
J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System.
Sanagawa A; Hotta Y; Kataoka T; Maeda Y; Kondo M; Kawade Y; Ogawa Y; Nishikawa R; Tohkin M; Kimura K
Cancer Med; 2018 Jun; 7(6):2269-2279. PubMed ID: 29663729
[TBL] [Abstract][Full Text] [Related]
20. Association Between Bortezomib Therapy and Eyelid Chalazia.
Fraunfelder FW; Yang HK
JAMA Ophthalmol; 2016 Jan; 134(1):88-90. PubMed ID: 26469392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]